CBFBeta: A Novel Therapeutic Target for Prostate Cancer

Abstract

Our proposal tests the idea that Core Binding Factor (CBF) should be targeted to achieve curative effects on AIPC. CBF is composed of a non-DNA binding component termed CBF and one of the DNA binding RUNX (RUNX1-3) proteins. CBF is a master transcriptional regulator of stem cell self-renewal, differentiation and homeostasis; defects in these regulatory pathways are the hallmark of all cancers, including prostate cancer. The purpose of this research is to test whether CBF contributes to the malignant phenotype of AIPC and to define gene expression changes associated with alterations to CBF. We have completed gene expression analysis of CBFbeta knockdown prostate cancer cells and find that malignant reversion is associated with altered expression of several microRNAs (miRNAs)including miRNA-663, a tumor suppressor in gastric cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jun 01, 2011
Accession Number
ADA550166

Entities

People

  • Shari Meyers

Organizations

  • Louisiana State University

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Androgens
  • Biomedical Research
  • Cancer
  • Cell Line
  • Cells
  • Department Of Defense
  • Gene Expression
  • Information Operations
  • Inhibitors
  • Instructions
  • Louisiana
  • Molecules
  • Neoplasms
  • Prostate Cancer
  • Proteins
  • Small Molecules

Fields of Study

  • Biology

Readers

  • Immunology and Pathology
  • Prostate Cancer Biology.

Technology Areas

  • Biotechnology